Symtuza - Revenue share — Total revenues
Gilead Sciences Symtuza - Revenue share — Total revenues increased by 3.8% to $138.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.1%, from $114.00M to $138.00M. Over 3 years (FY 2022 to FY 2025), Symtuza - Revenue share — Total revenues shows relatively stable performance with a -2.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market adoption or improved pricing power for the product, while a decrease may signal increased competition, patent expirations, or shifts in treatment guidelines.
Detailed definition
This metric represents the total revenue generated from the company's profit-sharing arrangement or royalty interest in...
Peer comparison
Comparable to royalty revenue or profit-share income reported by other pharmaceutical companies for licensed or co-developed therapeutic assets.
gild_segment_symtuza_revenue_share_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $132.50M | $132.50M | $132.50M | $132.50M | $132.25M | $132.25M | $132.25M | $132.25M | $141.00M | $168.00M | $139.00M | $144.00M | $114.00M | $124.00M | $124.00M | $133.00M | $138.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -0.2% | +0.0% | +0.0% | +0.0% | +6.6% | +19.1% | -17.3% | +3.6% | -20.8% | +8.8% | +0.0% | +7.3% | +3.8% |
| YoY Change | — | — | — | — | -0.2% | -0.2% | -0.2% | -0.2% | +6.6% | +27.0% | +5.1% | +8.9% | -19.1% | -26.2% | -10.8% | -7.6% | +21.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's symtuza - revenue share — total revenues?
- Gilead Sciences (GILD) reported symtuza - revenue share — total revenues of $138.00M in Q1 2026.
- How has Gilead Sciences's symtuza - revenue share — total revenues changed year-over-year?
- Gilead Sciences's symtuza - revenue share — total revenues increased by 21.1% year-over-year, from $114.00M to $138.00M.
- What is the long-term trend for Gilead Sciences's symtuza - revenue share — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's symtuza - revenue share — total revenues has grown at a -2.3% compound annual growth rate (CAGR), from $530.00M to $495.00M.
- What does symtuza - revenue share — total revenues mean?
- The total revenue earned by the company from its share of sales for the Symtuza HIV treatment.